- Trials with a EudraCT protocol (248)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
248 result(s) found for: Breast ultrasound.
Displaying page 1 of 13.
EudraCT Number: 2012-005349-20 | Sponsor Protocol Number: 2/2013 | Start Date*: 2013-01-15 | |||||||||||
Sponsor Name:Kuopio University Hospital | |||||||||||||
Full Title: Diagnostic accuracy of contrast-enhanced ultrasound-guided axillary core biopsy in preoperative staging of the newly diagnosed invasive breast cancer - a prospective study. | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014823-22 | Sponsor Protocol Number: LISER-M | Start Date*: 2009-07-28 | |||||||||||
Sponsor Name:AZIENDA USL DI FORLI` | |||||||||||||
Full Title: Second biopsy of axillary sentinel node in the local recurrence of breast cancer after mastectomy and first negative sentinel node. Studio LiSeR - M | |||||||||||||
Medical condition: patients with first local recurrence of breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003596-12 | Sponsor Protocol Number: C/21/07 | Start Date*: 2008-01-28 | |||||||||||
Sponsor Name:Imperial College of Science Technology and Medicine | |||||||||||||
Full Title: A neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer | |||||||||||||
Medical condition: This trial will involve postmenopausal patients with histologically confirmed breast tumours in whom it is felt cytoreductive systemic therapy would enable conservative surgery to be carried out. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2012-001889-14 | Sponsor Protocol Number: Bubble2012 | Start Date*: 2012-10-15 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: MicroBubble detection and Ultrasound guided Biopsy of axillary Lymph nodes in patients with Early breast cancer. | ||||||||||||||||||
Medical condition: Diagnosis of lymph node metastases in patients with newly diagnosed breast cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000436-27 | Sponsor Protocol Number: BR3031 | Start Date*: 2007-02-16 | |||||||||||
Sponsor Name:University of Birmingham [...] | |||||||||||||
Full Title: Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer. | |||||||||||||
Medical condition: Postmenopausal early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002061-12 | Sponsor Protocol Number: SBG2004-1/ABCSG25/GBG53 | Start Date*: 2007-08-17 | |||||||||||
Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | |||||||||||||
Full Title: PANTHER (The SBG 2004-1/ABCSG 25/GBG53 Protocol) - a randomised phase III study: Comparing two weekly and tailored epirubicin + cyclophosphamide followed by two weekly tailored docetaxel (dtEC->dtT... | |||||||||||||
Medical condition: lymph node positive breast cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) FI (Prematurely Ended) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003509-41 | Sponsor Protocol Number: GBG90 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien... | |||||||||||||
Medical condition: Patients with triple negative or HRpositive, early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016743-18 | Sponsor Protocol Number: ICG10 | Start Date*: 2010-02-02 |
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||
Full Title: A feasibility study of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer | ||
Medical condition: Primary breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004098-24 | Sponsor Protocol Number: GEP 04/0606 | Start Date*: 2008-01-14 | |||||||||||
Sponsor Name:FNCLCC | |||||||||||||
Full Title: A phase II, randomized, multi-center study, assessing value of adding RAD 001 to Trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery | |||||||||||||
Medical condition: HER-2 overexpressing primary operable breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003995-23 | Sponsor Protocol Number: GBG52 | Start Date*: 2009-03-31 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an in... | |||||||||||||
Medical condition: Primary breast cancer at non-frail, eldery male and female patients | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004503-23 | Sponsor Protocol Number: CS-2015-1 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nucelar Medicine and PET | |||||||||||||
Full Title: Phase II trial: uPAR-PET for preoperative staging of breast cancer patients | |||||||||||||
Medical condition: breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001943-21 | Sponsor Protocol Number: IFG-08-2019 | Start Date*: 2021-05-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Institut für Frauengesundheit GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: NeoOn – Neoadjuvant treatment of Ontruzant® (SB3) in patients with HER2-positive early breast cancer: An open-label, multicenter, phase IV study | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Female patients with early HER2positive breast cancer, neoadjuvantly treated. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004144-23 | Sponsor Protocol Number: 26866138-BCA-2001 | Start Date*: 2007-02-12 | |||||||||||
Sponsor Name:AZ St Augustinus, Wilrijk | |||||||||||||
Full Title: Clinical Trial Application for a Phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance. | |||||||||||||
Medical condition: breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004909-33 | Sponsor Protocol Number: LCTU122 | Start Date*: 2015-09-21 | ||||||||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | ||||||||||||||||||
Full Title: Thrombin Inhibition Preoperatively in Early Breast Cancer | ||||||||||||||||||
Medical condition: Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000819-67 | Sponsor Protocol Number: MTW_2020_KC01 | Start Date*: 2020-07-28 |
Sponsor Name:Maidstone and Tunbridge Wells NHS Trust | ||
Full Title: SENTINUS: Technical feasibility and diagnostic accuracy of intradermal microbubbles and contrast enhanced ultrasound to identify sentinel lymph node metastases in breast cancer patients following t... | ||
Medical condition: Breast Cancer - Using SonoVue injected intradermally into the breast and contrast enhanced ultrasound to see if the cancer has spread via lymphatic channels to sentinel lymph nodes in the axilla. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000393-20 | Sponsor Protocol Number: AX-CES1.2020 | Start Date*: 2020-10-23 | |||||||||||
Sponsor Name:DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA | |||||||||||||
Full Title: USE OF SULFUR HEXAFLUORIDE MICROBUBBLES IN INTRAOPERATIVE SURGICAL EVALUATION OF AXILLARY LYMPH NODES IN LOCO-REGIONAL ANESTHESIA BREAST SURGERY: COMPARISON WITH THE TRADITIONAL METHODICAL. PRELIMI... | |||||||||||||
Medical condition: Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003960-22 | Sponsor Protocol Number: WOO2 | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:Medical University of Innsbruck | |||||||||||||
Full Title: Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | |||||||||||||
Medical condition: (ER+) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009597-27 | Sponsor Protocol Number: BAY86-4875/91743 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bayer Health Care AG (study performed by Bayer Schering Pharma AG) | |||||||||||||
Full Title: An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1... | |||||||||||||
Medical condition: Patients with histologically confirmed breast cancer referred to MRM prior to surgery after XRM. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004389-33 | Sponsor Protocol Number: 5063562 | Start Date*: 2020-07-10 | |||||||||||||||||||||
Sponsor Name:Olli Lahtinen | |||||||||||||||||||||||
Full Title: Contrast enhanced ultrasound a novel technique in lymphatic imaging – A Prospective study | |||||||||||||||||||||||
Medical condition: | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FI (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018389-22 | Sponsor Protocol Number: LAP113957 / SOLTI-1001 | Start Date*: 2010-09-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compar... | |||||||||||||
Medical condition: patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) AT (Prematurely Ended) FR (Completed) NO (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
